A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic.

Published on Jun 30, 2021in Clinical and Translational Radiation Oncology
· DOI :10.1016/J.CTRO.2021.06.002
Ifigenia Vasiliadou1
Estimated H-index: 1
(Guy's and St Thomas' NHS Foundation Trust),
David Noble + 23 AuthorsS.A. Bhide14
Estimated H-index: 14
(The Royal Marsden NHS Foundation Trust)
Sources
Abstract
Abstract null null Background null The onset of the COVID-19 pandemic necessitated rapid changes to the practice of head and neck oncology. This survey was conducted to assess the pre-Covid-19 pandemic standard of practice for head and neck oncology patients and the treatment modifications introduced during the Covid-19 pandemic in UK. null null null Methodology null The UK National Cancer Research Institute (NCRI) Head and Neck Clinical Studies Group initiated a multi-centre survey using questionnaire to investigate the effect on feeding tube practice, radiotherapy (RT) fractionation and volumes, use of chemotherapy in the neo-adjuvant, adjuvant and palliative setting, the use of immunotherapy in the palliative setting, access to radiology and histopathology services, availability of surgical procedures. null null null Results null 30 centres were approached across UK; 23 (76.7%) centres responded and were included in the survey. There were differences in the standard practices in feeding tube policy, RT dose and fractionation as well as concurrent chemotherapy use. 21 (91%) participating centres had at least one treatment modification. 15 (65%) centres initiated a change in radical RT; changing to either a hypofractionation or acceleration schedule. For post-operative RT 10 centres (43.5%) changed to a hypofractionation schedule.12 (52.2%) centres stopped neo-adjuvant chemotherapy for all patients; 13 (56.5%) centres followed selective omission of chemotherapy in concurrent chemo-radiotherapy patients, 17 (73.9%) centres changed first-line chemotherapy treatment to pembrolizumab (following NHS England’s interim guidance) and 8 (34.8%) centres stopped the treatment early or offered delays for patients that have been already on systemic treatment. The majority of centres did not have significant changes associated with surgery, radiology, histopathology and dental screening. null null null Conclusion null There are variations in the standard of practice and treatment modifications for head and neck cancer patients during Covid-19 pandemic. A timely initiative is required to form a consensus on head and neck cancer management in the UK and other countries.
📖 Papers frequently viewed together
5 Citations
2 Citations
4 Citations
References23
Newest
#1Sultan Abdul-Jawad ('KCL': King's College London)H-Index: 5
#2Luca Bau (University of Oxford)H-Index: 11
Last. Sheeba IrshadH-Index: 1
view all 51 authors...
Summary Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumour type, stage and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for haematological malignancies, with virus-exposed patients colle...
25 CitationsSource
#1Francesco Passamonti (University of Insubria)H-Index: 84
#2Chiara CattaneoH-Index: 18
view all 74 authors...
Summary Background Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hosp...
109 CitationsSource
#1Hisham Mehanna (University of Birmingham)H-Index: 44
2 CitationsSource
#1David J Thomson (University of Manchester)H-Index: 11
#2David A. Palma (UWO: University of Western Ontario)H-Index: 55
Last. Sue S. Yom (UCSF: University of California, San Francisco)H-Index: 40
view all 32 authors...
Introduction Due to the unprecedented disruption of health care services by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC), in a time of heightened risk for patients and staff, and of limited resources. Methods A panel of international experts from ASTRO, ESTRO and select Asia-Pacific co...
105 CitationsSource
#1Hisham Mehanna (University of Birmingham)H-Index: 44
#2John Hardman (National Health Service)H-Index: 7
Last. F. Christopher Holsinger (Stanford University)H-Index: 50
view all 48 authors...
Summary The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of three rounds with 40 international experts in he...
47 CitationsSource
#1Lennard Y W Lee (University of Birmingham)H-Index: 6
#2Jean-Baptiste Cazier (University of Birmingham)H-Index: 39
Last. Gary Middleton (University of Birmingham)H-Index: 50
view all 39 authors...
Summary Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with can...
434 CitationsSource
#1Kevin J. Harrington (ICR: Institute of Cancer Research)H-Index: 98
#2S.A. Bhide (The Royal Marsden NHS Foundation Trust)H-Index: 14
Last. KH Wong (The Royal Marsden NHS Foundation Trust)H-Index: 4
view all 15 authors...
3 CitationsSource
#1Kimberley L. Kiong (University of Texas MD Anderson Cancer Center)H-Index: 5
#2Theresa Guo (University of Texas MD Anderson Cancer Center)H-Index: 21
Last. Stephen Y. Lai (University of Texas MD Anderson Cancer Center)H-Index: 55
view all 10 authors...
Kimberley L Kiong MBBS 1 , Theresa Guo MD 1 , Christopher MKL Yao MD 1 , Neil D Gross MD 1 , Matthew M Hanasono MD 2 , Renata Ferrarotto, MD 3 , David I Rosenthal MD 4 , Jeffrey N Myers MD 1 , Ehab Y Hanna MD1, Stephen Y Lai MD 1 1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States 2 Department of Plastics and Reconstructive Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States 3Department of Thoraci...
18 CitationsSource
#1Dana L. Crosby (SIU: Southern Illinois University Carbondale)H-Index: 6
#1Dana L. Crosby (SIU: Southern Illinois University Carbondale)H-Index: 3
Last. Arun Sharma (SIU: Southern Illinois University Carbondale)H-Index: 25
view all 2 authors...
OBJECTIVE: Due to the current coronavirus disease 2019 (COVID-19) pandemic, otolaryngologists face novel challenges when treating patients with head and neck cancer. The purpose of this review is to evaluate the current evidence surrounding the treatment of these patients during this pandemic and to provide evidence-based recommendations with attention to increased risk in this setting. DATA SOURCES: A review of the literature was performed with PubMed. Because recently published articles on thi...
13 CitationsSource
#1Erick Yuen (MUSC: Medical University of South Carolina)H-Index: 1
#2Gianna M. Fote (UCI: University of California, Irvine)H-Index: 8
Last. Terry A. Day (MUSC: Medical University of South Carolina)H-Index: 46
view all 10 authors...
15 CitationsSource
Cited By0
Newest